This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1m52

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1m52.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1m52.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1m52| PDB=1m52 | SCENE= }}
{{STRUCTURE_1m52| PDB=1m52 | SCENE= }}
-
'''Crystal Structure of the c-Abl Kinase domain in complex with PD173955'''
+
===Crystal Structure of the c-Abl Kinase domain in complex with PD173955===
-
==Overview==
+
<!--
-
The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia. Small molecule inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia. We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis). Both compounds bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways. As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate. In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase. The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex. In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571. The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.
+
The line below this paragraph, {{ABSTRACT_PUBMED_12154025}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 12154025 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_12154025}}
==About this Structure==
==About this Structure==
Line 35: Line 39:
[[Category: Kinase inhibitor]]
[[Category: Kinase inhibitor]]
[[Category: Pd173955]]
[[Category: Pd173955]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 00:38:31 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jul 2 23:13:41 2008''

Revision as of 20:13, 2 July 2008

Image:1m52.png

Template:STRUCTURE 1m52

Crystal Structure of the c-Abl Kinase domain in complex with PD173955

Template:ABSTRACT PUBMED 12154025

About this Structure

1M52 is a Single protein structure of sequence from Mus musculus. Full crystallographic information is available from OCA.

Reference

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)., Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J, Cancer Res. 2002 Aug 1;62(15):4236-43. PMID:12154025

Page seeded by OCA on Wed Jul 2 23:13:41 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1m52"
Personal tools